Overview
Makoto (“Mak”) focuses on helping clients build, protect, and deploy their intellectual property assets with a global perspective. Mak’s practice includes client counseling and global portfolio management in intellectual property, patent prosecution, IP due diligence, and licensing. He has experience in a wide range of technologies, including biopharmaceuticals, biotechnology, bioinformatics, diagnostics, personalized medicine, medical devices, microelectromagnetic systems (MEMS), and computer software.
Clerk Experience
Judicial extern to the Honorable Susan Y. Illston, U.S. District Court, Northern District of California, 2018.
Education
- University of California - Berkeley - School of Law (J.D., 2019)
- University of California - San Francisco (Ph.D. Cell Biology, 2008)
- Amherst College (B.A. Biology, 2000), Magna cum laude
News & Insights
Articles
Litigation Blog
- Famous Trademark Not Abandoned After Original Owner’s Bankruptcy
- What’s in a Name?: Third Party Use of a Descriptive Term Without Secondary Meaning Can Undermine Assertions of Substantially Exclusive Use of the Term
- Ineffective Skinny Label Leaves Generic Liable Despite Effort to Carve-Out the Patented Indication
- Copying From a Copyrighted Computer Program May Be Fair Use to the Extent Needed to Promote Adoption of the Use of Accrued Talents in Creating a New Software Platform
- Non-Disclosure Agreement Controls Ownership of Patents Arising From Confidential Information Received Thereunder
- Government’s Pre-Litigation Conduct Cannot Justify a Court of Claims Fee Award
- Intrinsic Evidence Establishing the Context of a Claim Term Can Limit Claim Scope
- En Banc Federal Circuit Denies Rehearing of Holding That Severance of an Unconstitutional Restriction in the America Invents Act Is Consistent With Congressional Intent and Is the Least Disruptive Solution
Biotechnology Blog
- Practical Application and Particular Treatment: What the USPTO’s December 4 Memorandum Means for Life Sciences §101 Eligibility
- FDA Announces Review of New Clinical Trials That Export Americans’ Biological Samples to Hostile Countries
- U.S. Supreme Court Defers to Agency Decision-Making in FDA’s Denial of Premarket Approval of Flavored E-Cigarette Products
- Novo Nordisk Seeks to Block Compounded Versions of Diabetes / Weight Loss Drug
- FDA Approves Colony Stimulating Factor-1 Receptor (Csf-1R) Blocking Antibody for Treatment of Chronic Graft-Versus-Host Disease (Cgvhd)
- Flavored E-cigarette Manufacturers Face Regulatory Challenges
Latest Updates and News
Practical Application and Particular Treatment: What the USPTO’s December 4 Memorandum Means for Life Sciences §101 Eligibility
The USPTO’s December 4, 2025 memorandum on Subject Matter Eligibility Declarations (SMEDs) seeks to raise awareness of the “underutilized path” of submitting Rule 132 declarations, referred to as “SMEDs”, for...
Knobbe Martens Announces Six New Partners in Offices Across the Country
New partner class strengthens Knobbe Martens’ position as a leader in IP Law IRVINE, Calif., January 5, 2026 – Knobbe Martens, a leading intellectual property and technology law firm, is...
FDA Announces Review of New Clinical Trials That Export Americans’ Biological Samples to Hostile Countries
On June 18, 2025, the U.S. Food and Drug Administration (FDA) announced that it will review new clinical trials that involve sending biological samples to “hostile countries,” to prevent exploitation...
U.S. Supreme Court Defers to Agency Decision-Making in FDA’s Denial of Premarket Approval of Flavored E-Cigarette Products
We previously reported a decision by the U.S. Food and Drug Administration (FDA), denying the premarketing authorization of several flavored e-cigarette product.[1] On April 2, 2025, the Supreme Court of...
Novo Nordisk Seeks to Block Compounded Versions of Diabetes / Weight Loss Drug
On October 22, 2024, Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide products (WEGOVY, OZEMPIC and RYBELUS) to be included in...
FDA Approves Colony Stimulating Factor-1 Receptor (Csf-1R) Blocking Antibody for Treatment of Chronic Graft-Versus-Host Disease (Cgvhd)
On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO (axatilimab-csfr) developed by Incyte Corporation (and in-licensed from Syndax Pharmaceuticals), for treatment of chronic graft-versus-host disease (cGvHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
